Glycopyrrolate Injection Recalled Due to Manufacturing Quality Deviations
Accord Healthcare is recalling Glycopyrrolate Injection (4 mg/20 mL) from two batches due to CGMP deviations identified during FDA inspection. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall due to manufacturing quality deviations (CGMP) identified during regulatory inspection. No illnesses or injuries have been reported; the hazard relates to potential quality and safety risks from manufacturing defects.
Plain-English summary
Accord Healthcare, Inc. is recalling Glycopyrrolate Injection, USP (4 mg/20 mL, 0.2 mg/mL) across the United States, Puerto Rico, and Canada. The recall affects 322 vials from two batches: R2200431 (expiration 7/31/2023) and R2200439 (expiration 9/30/2023). The product is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations in the manufacturing process. CGMP standards ensure drugs are manufactured under safe, quality conditions. No illnesses or injuries related to this product have been reported.
If you have received this product, do not use it. Patients and healthcare providers should consult with a pharmacist or healthcare provider about alternative treatments. This product may not meet established quality standards due to the identified manufacturing deviations.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Injectable
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batches: R2200431
- Exp. Date 7/31/2023
- R2200439
- Exp. Date 9/30/2023
UPCs (6)
- 0316729474054
- 0316729472302
- 0316729473316
- 0316729471633
- 316729474054
- 316729474030
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- ModerateGlycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
FDA (Drugs) · 2023-06-14
- HighPrescription Glycopyrrolate Injection Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-03-08
- HighGlycopyrrolate Injection, USP recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateGlycopyrrolate injection recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateClomiphene Citrate USP Active Pharmaceutical Ingredient Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-15
- SevereBortezomib for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15